Document:

Amendment No. 3, dated January 17, 2007, to Development and License Agreement

 Exhibit 4.42 
 AMENDMENT NO. 3 
 to 
 DEVELOPMENT AND LICENSE AGREEMENT 
 between 
 GLAXO GROUP LIMITED 
 and

 ADHEREX TECHNOLOGIES INC. 
 THIS AMENDMENT NO. 3 (this “Third Amendment”) effective on this 17th day of January, 2007 (the “Third Amendment Effective Date”), is entered into by and between Glaxo Group Limited, a company organized under the
laws of England and Wales, having its registered office at GlaxoWellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN United Kingdom (“GGL”) and Adherex Technologies Inc., a company organized under the laws of Canada and
having an office located at 4620 Creekstone Drive, Suite 200, Durham, North Carolina, 27703 USA (“Adherex”): 
 RECITALS

 A. The Parties entered into the Development and License Agreement, effective as of July 14, 2005 (the “Agreement”). 
 B. The Parties entered into Amendment No. 1 to the Agreement, effective December 20, 2005, relating to the ExherinTM Option. 
 C. The Parties entered into Amendment No. 2 to the Agreement, effective June 23, 2006, relating to Eniluracil. 
 D. The Parties now desire to further amend the Agreement to reflect the expiration of the GGL Options under the Agreement on the terms and conditions set forth below.

 NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties, intending to be legally bound, hereby
amend the Agreement and otherwise agree as follows: 
 1. Defined Terms. All terms used in this Third Amendment but not defined herein shall have the
same meaning as set forth in the Agreement. 
 2. Accelerated Expiration of Option B, Option C, and Option E; Effect. The Parties agree that,
notwithstanding Sections 2.4, 2.4.2, 2.4.3 and 2.4.8 of the Agreement, Option B, Option C, and Option E shall expire on March 1, 2007 (the “Closing Date”), subject to Adherex’s payment and satisfaction of the Buy-Out Price as
provided in Section 5 below. Upon payment by Adherex of the Buy-Out Price: (i) GGL shall have no further option or right to Develop or Commercialize Eniluracil, unless otherwise agreed by the Parties; (ii) the Agreement shall continue
in full force and effect as if GGL had exercised none of the GGL Options; (iii) all references in the Agreement to activities, actions or responsibilities of GGL 

 
on exercise of a GGL Option shall have no further force or effect; and (iv) this Third Amendment shall have no effect on Adherex’s obligations to
Develop and Commercialize Eniluracil on expiration of the GGL Options, as provided in the Agreement, with payment to GGL of the milestones and royalties set forth in Sections 8.1, 8.2 and 8.3. 
 3. Deletion of Section 2.4.4. Section 2.4.4 of the Agreement is hereby deleted in its entirety from the Agreement. 
 4. Disbanding of JSC; Updates to GGL. Upon the Closing Date, the JSC shall be disbanded. Article 3 of the Agreement is hereby deleted in its entirety, and all
references to the JSC in the Agreement are hereby deleted. Commencing upon the Closing Date, Adherex shall provide GGL with written updates of Development progress and efforts on at least a quarterly basis and will provide GGL with any information
regarding Development of Eniluracil by Adherex, its Affiliates or its sublicensees as reasonably requested by GGL. 
 5. Buy-Out of Option B, Option C and
Option E. On or before the Closing Date, Adherex shall pay GGL one million US Dollars (US $1,000,000) in consideration for GGL’s agreement to allow the GGL Options to expire (the “Buy-Out Price”) as set forth in Section 2. If
Adherex fails to make the payment of the Buy-Out Price to GGL on or before the Closing Date, this Third Amendment shall have no force or effect, and the Agreement shall continue in full force and effect, as amended prior to this Third Amendment.

 6. Manner of Payment of Buy-Out Price. On the Closing Date Adherex shall pay the Buy-Out Price to GGL by electronic wire transfer into an account
designated in writing by GGL. 
 7. Binding Effect. This Third Amendment shall be binding upon and inure to the benefit of the Parties hereto, their
permitted successors, legal representatives and assigns. 
 8. Waiver. No waiver of any term or condition of this Third Amendment will be
effective unless set forth in a written instrument that explicitly refers to this Third Amendment that is duly executed by or on behalf of the waiving Party. No waiver by any Party of any term or condition of this Third Amendment, in any one or more
instances, will be deemed to be or construed as a waiver of the same or any other term or condition of this Third Amendment on any prior, concurrent or future occasion. Except as expressly set forth in this Third Amendment, all rights and remedies
available to a Party, whether under this Third Amendment or afforded by Law or otherwise, will be cumulative and not in the alternative to any other rights or remedies that may be available to such Party. 
 9. Severability. If any provision of this Third Amendment is held to be invalid, illegal or unenforceable in any respect, that provision will be limited or
eliminated to the minimum extent necessary so that this Third Amendment will otherwise remain in full force and effect and enforceable. 

 10. Governing Law. This Third Amendment will be construed, and the respective rights of the Parties determined,
according to the substantive law of the State of North Carolina without regard to the provisions governing conflict of laws. 
 11. Counterparts. This
Third Amendment may be executed in any two counterparts, each of which, when executed, will be deemed to be an original and both of which together will constitute one and the same document. 
 12. Continuing Effect. All other terms and conditions of the Agreement shall remain in full force and effect. 
 IN WITNESS WHEREOF, Glaxo Group Limited and Adherex Technologies Inc., by their duly authorized representatives, have executed this Amendment No. 3 as of the Third
Amendment Effective Date. 
  

									
	GLAXO GROUP LIMITED	 		  	ADHEREX TECHNOLOGIES INC.
					
	By:	 	 /s/ Paul Williamson
	 		  	By:	  	 /s/ William P. Peters

					
	Name:	 	 Paul Williamson
	 		  	Name:	  	 William P. Peters

	Title:	 	 For and on behalf of
Edinburgh Pharmaceutical
Industries Limited
Corporate Director
	 		  	Title:	  	 Chairman & CEOAmendment to Employment Agreement

 Exhibit 10.1 
 AMENDMENT TO EMPLOYMENT AGREEMENT 
 This AMENDMENT TO EMPLOYMENT AGREEMENT is dated as of the
15th day of January, 2007 by and between Super Vision International, Inc., a Delaware Corporation (“SVI”) and Michael A. Bauer (the “Employee”). 
 Background 
 A. SVI and the Employee entered into an Employment Agreement dated
as of September 9, 2005 (the “Agreement”). 
 B. SVI and the Employee desire to amend the Agreement upon the terms and
conditions set forth in this Amendment. 
 Agreement 
 NOW, THEREFORE, in consideration of the mutual promises and covenants contained in the Agreement and this Amendment, the parties hereto agree as follows: 
 1. Definitions. Capitalized terms used herein and not otherwise defined have the respective meanings set forth in the Agreement. 
 2. Amendments to the Agreement. In accordance with Section 8(a) of the Agreement, the Agreement is hereby amended as follows: 
 2.1 Section 1(e) of the Agreement is amended in its entirety to read as follows: 
 “(e) Stock Options. On the Signing Date, Employee will be granted a stock option to purchase 40,000
shares of Employer’s Class A common stock at an exercise price equal to the fair market value of such shares on the date of grant as determined by the Compensation Committee. Such option shall fully vest as to all 40,000 of the shares
subject to the option on the Signing Date. Subject in all instances to Employee’s continued employment with Employer, on January 1, 2007, Employer shall grant Employee an option to purchase 25,000 shares of Employer’s Class A
common stock at an exercise price equal to the fair market value of such shares on the Signing Date. Provided that the revenue milestones set forth in Employer’s 2006 Board approved operating plan are achieved this option shall vest as to
25,000 shares subject to such option on January 15, 2007. Subject in all instances to Employee’s continued employment with Employer, on January 1, 2008, Employer shall grant Employee an option to purchase 75,000 shares of
Employer’s Class A common stock at an exercise price equal to the fair market value of such shares on the Signing Date. Provided that the revenue and net income before taxes milestones set forth in Employer’s 2007 Board approved
operating plan are achieved this option shall vest as to 25,000 shares subject to such option on January 15, 2008 and 50,000 shares on March 31, 2008, respectively. If a revenue and net 

 
income before taxes milestone is not achieved, but Employer achieves at least 25% of such milestone, than an option shall vest with respect to a
corresponding pro rata percentage of shares on the relevant vesting date. For example, if Employer achieves 50% of the targeted net income before taxes milestone for 2006, 25,000, or 50%, of the shares subject to the applicable option shall vest on
March 31, 2007. All such options shall be subject to the terms and conditions of Employer’s stock option plan pursuant to which the options are granted and shall be conditioned upon Employee’s execution of a stock option agreement
with Employer in the form specified by the Compensation Committee. 
 For purposes of this Agreement, net income before taxes shall be
determined without regard to any gains, losses, profits, charges or expenses realized by the Company from any legal proceeding to which the Company is a party that is pending on the Effective Date including, without limitation, awards to Employer of
attorneys’ fees and costs incurred by Employer in such proceedings and any legal fees or costs of any party to such proceedings, other than Employer, that are paid by Employer. 
 2.2 Schedule 1 of the Agreement is amended in its entirety to read as set forth on Schedule 1 attached hereto. 
 3. Miscellaneous. 
 3.1 Except as
specifically amended hereby, the remaining terms and provisions of the Agreement shall not be affected by this Amendment and shall remain in full force and effect. 
 3.2 This Amendment may be executed in any number of counterparts, each of which counterpart shall be deemed to be an original, and such counterparts shall constitute but one and the same instrument. 
 3.3 This Amendment shall be governed in all respects by the laws of the State of Florida. 
 3.4 The term “Agreement” as used in the Agreement and all other instruments and agreements executed thereunder shall for all purposes refer to
such Agreements, respectively, as amended by this Amendment. 
 3.5. This Amendment shall not be considered a waiver by the parties of the
observance of any term or breach of the Agreement and shall not be construed as a waiver of any subsequent non-observance or breach of that term or any other term of the same or a different nature. 
 Super Vision International, Inc. 
 Amendment to
Employment Agreement 
 Page 2 of 3 

 The undersigned have executed this Amendment as of the day and year first written above. 
  

			
	SUPER VISION INTERNATIONAL, INC.,
	a Delaware corporation
		
	By:	 	 /s/ Brett M. Kingstone

		 	Brett M. Kingstone, Chairman of the Board
	
	EMPLOYEE:
	
	 /s/ Michael A. Bauer

	Michael A. Bauer

 Super Vision International, Inc. 
 Amendment to Employment Agreement 
 Page 3 of 3 

					
	 Compensation Plan
	 	Effective Date:	 	 1/1 to 12/31/2006

	 President & CEO
	 		 	
		 	Plan Update:	 	 2-Nov-06

			
	 Employee
	 	Mike Bauer	 	

  

												
	 	  	 	 	 	 	  	Annualized Value
		  	Income Package:	  			 			  		
		  	Base Salary:	  			 			  	$	180,000
					
		  	Additional: Car Allowance	  			 			  	$	12,000
				
		  	Target Bonus	  	% of Total Comp: 50%	  	$	190,000
		  	Target Total Compensation	  			 			  	$	382,000
					
		  	Part 1: Earnings Achievement	  			 			  		
		  		  			 			  	 	 
		  	Total Bonus Objective:	  			 			  	$	150,000
		  		  			 			  	 	 
		  	1a. Gross Margin	  	25	%	 	$	37,500	  		
		  		  	 	 	 	 	 	  		
		  	 Pay-out:
	  			 			  		
		  	 Upon achieving 40% Gross Margin
	  	100	%	 	$	37,500	  		
		  	 Upon achieving 40.5% Gross Margin
	  	105	%	 	$	39,375	  		
		  	 Upon achieving 41% Gross Margin
	  	110	%	 	$	41,250	  		
		  	 Upon achieving 41.5% Gross Margin
	  	120	%	 	$	45,000	  		
		  		  	 	 	 	 	 	  		
		  	1b. Net Operating Profit	  	75	%	 	$	112,500	  		
		  		  	 	 	 	 	 	  		
		  	Based on achieving the 2006 budgeted Net Operating income, after bonus allocation and audited results	  			 			  		
					
		  	Part 2: Management Achievement	  			 			  		
		  		  			 			  	 	 
		  	Total Bonus Objective:	  			 			  	$	40,000
		  		  			 			  	 	 
		  	Paid out on the completion of the following items:	  			 			  		
	 1.
	  	Achieve Top Line Revenue Budget for 2006	  	25	%	 	$	10,000	  		
	 2.
	  	Manage overall operating expense budget for 2006	  	25	%	 	$	10,000	  		
	 3.
	  	Complete equity financing prior to 12/31/2006	  	50	%	 	$	20,000	  		
					
		  	Part 3: Stock Option Incentive	  			 			  		
	 1.
	  	CEO Agreement Date	  	40,000 Stock Options	  		
	 2.
	  	January 15, 2007 - achievement of 2006 revenue in approved budget	  	25,000 Stock Options	  	 
 
 
 	Note: Stock options will be
prorated if performance does
not
exceed 100%, but
still achieves 25%.

  

			
		 	 /s/ Brian McCann

	 Prepared by Compensation Committee:
	 	Brian McCann
		
		 	 /s/ Fritz Zeck

		 	Fritz Zeck
		
		 	 /s/ Tony Nicolosi

		 	Tony Nicolosi
		
		 	 Date: January 15, 2007

		
		 	 /s/ Michael A. Bauer

	 Reviewed and Accepted by:
	 	Michael A. Bauer - President & CEO
		
		 	 Date: January 15, 2007

	**	This plan supersedes and cancels any and all other commission or bonus programs.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}]]